Please assess the completion status of the following clinical trial:

Trial Title: Botulinum Toxin for Pelvic Pain in Women With Endometriosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~* Female gender~* Age between 18 and 55~* History of endometriosis at surgery~* Persistent pelvic pain for at least 3 months~* Pelvic floor spasm~* Negative pregnancy test (in women who have not had a hysterectomy)~* Willing to use reliable method of contraception for the month after botulinum toxin injection including oral contraceptives, IUD, and barrier with spermicide.~* Willing and able to give informed consent~* Willing and able to comply with study requirements~EXCLUSION CRITERIA:~* Women with other causes of chronic pelvic pain including infectious, gastrointestinal, psychological disorders, fibromyalgia and chronic fatigue syndrome based on review of medical history within 1 year of first study visit,~* Untreated severe cervical dysplasia or other gynecologic condition clinically significant abnormalities on physical or laboratory examinations that require evaluation or treatment or that would make participation unsafe~* Hysterectomy and bilateral salpingo-oophorectomy~* Pregnancy~* Lactation~* Allergy to albumen or botulinum toxin~* Presence of antibodies to botulinum toxin or loss of response to previous injections for any indication~* A known neuromuscular junction disorder such as myasthenia gravis or Eaton-Lambert syndrome~* History of urinary or fecal incontinence~* Known pelvic prolapse~  * Eligibility will be based on a physical exam at NIH at the first study visit, as well as history and available medical records within 1 year before the study visit. Negative test results will be documented to confirm study eligibility. If the Pap and the GC and chlamydia tests were not done outside of the NIH within the previous year, or if documentation of the negative test results is not available, we will await the results of the screening tests done at the NIH before administering the study medication.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Botulinum toxin (BoNT) (Type: EXPERIMENTAL): OnabotulinumtoxinA 100 Units diluted in 4cc saline, one time intramuscular administration
- Placebo (Type: PLACEBO_COMPARATOR): Saline, 4cc, one time intramuscular administration

Based on this trial design, predict the completion outcome and termination type (if applicable).